Search

My ophthalmic elective: focusing on myopia in Taiwan

The authors describe their elective experience and delve further into high myopia, an emerging ophthalmic disease that is increasingly recognised in and outside Asia. The medical school elective programme presents an opportunity for students to conduct learning in their chosen...

What’s next in retinal imaging? Faster, deeper and full-on

Fast-evolving technological leaps are opening the way toward clinically useful ocular coherence angiography, generating 3-dimensional microvasculature maps without intravenous dye injection, as well as whole-eye imaging, handheld patient-operated optical coherence tomography (OCT) devices and, for challenging vitreoretinal procedures, integrated intraoperative...

Are we short-sighted about myopia?

Worldwide prevalence of myopia has increased rapidly in recent years and has now reached epidemic levels, particularly in South-East Asia where prevalence is around 80% [1-4]. Myopia prevalence is also increasing in the United States and Europe where it is...

Evolving towards an interventional glaucoma mindset

Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...